Life Sciences Archive » January, 2023

Life Sciences - January, 2023

319 articles

• DEA Faulted Controls At Opioid Distributors, Ga. Jury Hears
• DC Circ. Revives FOIA Suit Seeking Execution Drug Info
• Amgen, Horizon Say FTC Is Reviewing Proposed $28B Merger
• Achaogen Claims Over Lost Ch. 11 Sales Can Go Forward
• CBD Co. Beats Some Claims By Ex-Stratton Oakmont Trader
• Nonprofit Takes French Fry Cancer Case To High Court
• J&J's Case Axed, But Door Not Shut On 'Texas 2-Step' Ch. 11s
• Riding Circuit: February's Notable Oral Arguments
• Meta Cites Privacy In COVID Misinformation Subpoena Fight
• Calif. Pot Regulators Ask State AG About Interstate Pot Trade
• Consumers Raise Stink About Diaper Genie's 1-Yr. Supply Ads
• What 2023 Has In Store For The Cannabis Industry
• ImmunoGen Loses Trial Bid To Secure Cancer Therapy Patent
• AngioDynamics Fights For New Trial In CR Bard Patent Case
• Lessons From Fed. Circ. Ruling On Lung Disease Patent
• Biotech Goosed Stock With Omicron Vax Claims, Suit Says
• Cipla Files Fresh Bid To Revoke Bayer's Xarelto Patent
• Opioid Victim Families Go To Trial Against Distributors In Ga.
• Feds Call Convicted Theranos COO Balwani A 'Flight Risk'
• White House To End COVID-19 Emergency Declarations In May
• Bernstein Litowitz Nabs $7.7M Fees In Stericycle Case
• Ex-Outcome Health Execs' Greed Led To $1B Fraud, Jury Told
• Canadian Pharma Co.'s Units File $61M Ch. 15 In Delaware
• New ACA Birth Control Exemptions Cover Faith, Not Morality
• Walgreens To Pay $7M In FCA Suit Over Hepatitis C Drugs
• Cooley-Led Biotech Firm Launches Plans For $125M IPO
• PTAB Rules Against Apple In Masimo Blood Oximetry IP Fight
• HHS Can't Force 'Unlimited' Drug Discounts, 3rd Circ. Says
• Investors Say Biopharma Execs Hid New Migraine Drug Issues
• Trending At The PTAB: Evidence For Priority Cases
• Mich. Doctor Gets 16 Years For $100M Opioid Pill Scheme
• Cannabis Cos. Must Brace For More Mislabeling Class Actions
• Mass. Launches Abortion Hotline Staffed By BigLaw, ACLU
• NY Hospital's Vax Firing Violated Bias Laws, Worker Says
• 3rd Circ. Throws Out J&J Talc Unit's 'Texas Two-Step' Ch. 11
• Pharma Co. Hit With 2nd Suit Over $1.8B AstraZeneca Deal
• Sen. Warren Wants FTC Scrutiny Of $29B Pharma Deals
• Benefits Co. Can't Escape J&J's Suit Over Patient Drug Fund
• Generic Zantac Makers Want Final Judgment In Fla. MDL
• Pharma Co. Appeals Malpractice Loss Against Polsinelli
• 5 Ways Attorneys Can Use Emotion In Client Pitches
• UK Litigation Roundup: Here's What You Missed In London
• Pharma Whistleblower Asks 2nd Circ. To Revive Kickback Suit
• California Exec Convicted Of $157M Drug Scheme
• Taylor Wessing Pursues 'Strategic Alliance' With Madrid Firm
• 2 Firms Lead Finnish Pharma Biz €12M Share Fundraising
• Investors Say Cannabis REIT Should Have Known About Ponzi
• IP Forecast: Intel To Spar With ParkerVision In Patent Trial
• 6th Circ. Vexed By Ex-Smuckers Workers' COVID-19 Vax Suit
• Ariz. Tribe Sues McKinsey Over Opioid Crisis
• Judge Won't Silence J&J's $3B Damages Estimate In IP Suit
• RFK Jr.-Repped Doc Wins Halt Of COVID Misinformation Law
• PTAB Upholds Testing Patents After Ravgen's $272M Jury Win
• Zantac Suits Consolidated In NY After Fla. MDL Tossed
• Tricida Gets OK To Seek Stalking Horse For Ch. 11 Auction
• GlaxoSmithKline Biased Against Older Workers, Chemist Says
• Drug Co. Ends Product Endorsement Fight With Ga. Professor
• Teva Can't Get HHS Docs For Kickback Defense
• In Blow To Hemp Industry, FDA Punts On CBD Rules
• AstraZeneca Sales Reps See Pay Bias Suit Axed, For Now
• Europe's New Unitary Patent System Will Affect IP Agreements
• Nichols Liu Adds Career Corporate Ethics Officer To DC Group
• SPAC Buys Longevity In $236.2M Deal Led By 2 Firms
• 5 Keys To A Productive Mediation
• Pfizer Bid To Shield FBI Talks Meets Skeptical Judge
• DC Circ. Questions FDA Appeal Process In E-Cig Case
• Jury To Decide If Allergan Sale Included Arbitration Clause
• Bristol-Myers Gets Pushback On Early Win Bid Over Cancer IP
• Regeneron Gets Novartis Syringe Patent Axed At PTAB
• Shareholders Sue Sotera After $363M Emissions Verdict
• Abortion Drug Restrictions Draw Challenges In W.Va., NC
• Gopuff Hits COVID-19 Test Supplier With $1.1M Contract Suit
• Tech Co. Drops Suit Over Wire Fraud Coverage
• Juul MDL Paused As 9th Circ. Reviews Class Certifications
• Horse Trainer Gets 5 Years In Doping Scheme
• Rare COVID Benefits Award Yields Workers' Comp Road Map
• Gilead Wants US To Face Defenses Before HIV Patent Trial
• Pension Fund Urges 11th Circ. To Revive Suit Against MiMedx
• New Clinical Trial Law Promotes Diversity And Modernization
• Investor Files Securities Suit Over $952M Albireo Merger
• Ex-Olympic Skater Pleads Guilty To COVID Relief Fraud
• 4th Circ. Weighs Help Of W.Va. Justices In Pelvic Mesh Appeal
• Purdue Warns Tribe's NY Lawsuit Could 'Blow Up' Ch. 11 Plan
• DOD, Ex-Sergeants Spar Over Dismissal Of Vax Mandate Row
• Procter & Gamble Duped DayQuil, Vitamin C Buyers, Suit Says
• Reed Smith Opens Orange County Office, Firm's 5th In Calif.
• Conducting M&A Transactions In A Challenging Market
• 1st Circ. Reels Aetna Back Into Knee Implant Libel Suit
• Kroger Seeks Insurance Coverage For Over 700 Opioid Suits
• Holmes Says Feds' Claims Of Mexico Escape Plans Are False
• Pharma Co. Faces Investor Suit Over $1.8B AstraZeneca Deal
• Novartis Tells Justices Judge Swap Wrongly Sunk Patent Win
• 11th Circ. Backs Fla. Man's Medicare Fraud Conviction
• Court Consolidates Takeda Antitrust Suits Over IBS Drug
• Bard Vascular Filter Case In Georgia Settles On Eve Of Trial
• High Court Won't Take On SEIU Union Dues Deduction Suit
• Judge Put On 'Blinders' In Merck Patent Fight, Fed. Circ. Told
• Evaluating The Legal Ethics Of A ChatGPT-Authored Motion
• After Catalyst Case, FDA Won't Stop Approving Orphan Drugs
• Developments To Watch In Trade Secret Practice This Year
• Velsicol Must Face Suit Over Pesticide Made By Predecessor
• Real Estate Rumors: Cointreau, Vanbarton, Sunshine Sachs
• Catching Up With Delaware's Chancery Court
• Former Troutman Pepper Attys Launch Goodwin Philly Office
• Juul's $255M Economic Loss MDL Deal To Get Green Light
• Attys For Takeda Employees Want $7.3M On 401(k) Lineup Suit
• J&J Unit Says Rival Is Still Flooding Market Despite Verdict
• Daiichi Slams Seagen's Bid To Nix Cancer Drug Patent Award
• FTC Wants Shkreli Held In Contempt Over Stonewalling
• Flint, Groups Set New Water Pipe Replacement Deadline
• A Look At The Legal Intersection Of AI And Life Sciences
• MoCRA: 6 Key Takeaways From The New Cosmetics Law
• AndroGel Patent Suit Ruled Baseless For Antitrust Claims
• Focus On Drug's Cancer-Killing Potential, Judge Tells Biotech
• Lessons On Prior Art From PTAB's Genetic Testing Decisions
• HHS Vows Audits, Publicity Targeting Nursing Home Practices
• Pharmacy Owner Convicted Of Paying $25M In Kickbacks
• Ex-CytoDyn CEO Sues In Del. Chancery Court For Legal Fees
• Defense Wants 'Rule-Breaking' Plaintiffs' Attys Off Wage Case
• Feds Say Elizabeth Holmes' Flight Risk 'Never Been Higher'
• NJ Judge Signs Off On $1.3M Atty Fee In Immunomedics Suit
• 7 Tips To Increase Your Law Firm's DEI Efforts In 2023
• Cancer Patient Files Civil Rights Suit Against Attys, Monsanto
• Keys To A 9-0 High Court Win: Get Back To Home Base
• High Court Legacy Of FCA Unity Teeters On Ideological Brink
• Exelixis Notches Win Against MSN In Cancer Drug Patent Trial
• IP Forecast: Pfizer Wants Talks With FBI Kept Under Wraps
• PPE Fraud Suit Ends In $2.1M Judgment For Fla. Reseller
• Juul Investor Seeks Limited Scope In April Vaping Trial
• J&J Unit Takes Aim At Doctors Linking Talc To Mesothelioma
• Indian Drug Distributor Gets 7 Years For Trafficking Pills In US
• Incorrect Inventorship On Patents Is A Tough Claim To Prove
• Ex-SPAC Founder Fights For Legal Fees Over Merger Probe
• Goodwin Adds Former Chief Counsel Of Health Agency's OIG
• Endo Gets Approval For Fee Deal With State Governments
• Justices Seek Feds' Input In Ex-Shkreli Atty's 401(k) Fight
• Supreme Court Says It Hasn't Identified Dobbs Leaker
• 5th Circ. Upholds Lincare's Win In Ex-Worker's Race Bias Suit
• EU Medicine Reboxing Ruling Gives Guidance To Pharma Cos.
• The 7th Circ.'s Top 10 Civil Opinions Of 2022
• Section 230 Saves Retailers From Model's Likeness Suit
• Walmart Aims To 'Weaken' Opioid Script Laws, DOJ Says
• Investors, Inovio Get Final OK For $44M Deal In Stock Suit
• 3 Firms Lead Biotech Deal With Wilbur Ross-Backed SPAC
• Becton Dickinson Investor Seeks Cert. In Pump Recall Suit
• Olly Can't Duck Claims Over Too Much Melatonin In Products
• Atty-Client Privilege Arguments Give Justices A Moving Target
• Jazz Pharma Unit Sues Over Cannabis Seizure Drug Patent
• W.Va. AG Inks $83M Opioid Deal With Walgreens
• Justices Ignite FCA Debate: Fairness Vs. 'Invitation To Fraud'
• FDA Urges Texas Judge Not To Reverse Abortion Pill Approval
• Fed. Circ. Urged Not To Reverse Jazz's Orange Book Delisting
• Calif. Wants High Court To Toss $302M J&J Mesh Fine Appeal
• Mich. County Loses Challenge To $800M Opioid Payout Plan
• 5 Gen X Characteristics That Can Boost Legal Leadership
• Pharma Co. Seeks $2M Fee For Bid In Canceled Ch. 11 Auction
• 10th Circ. Skeptical Of Forcing Arbitration In ESOP Row
• Catching Up With Delaware's Chancery Court
• Mallinckrodt Ruling Holds Creditor Lessons For IP Sellers
• Pfizer Asks Appeals Court To Limit Damages In Lyrica Suit
• Alabama Water District Joins PFAS MDL Against 3M, Others
• Endo Claimants Say It's Time For Alternative Ch. 11 Plans
• Pharmacies And Drug Cos. Want Out Of Texas Opioid MDL
• Attorneys See Sober Outlook For Deals After JP Morgan Event
• Life Sci Partners Tapped For Withers Boston Office
• What To Expect From Justices' FCA Scienter Standard Review
• Voyager Sells Digital Assets For $1B, FTX Finds $5B In Crypto
• 6th Circ. Slams Door On Wholesaler's Opioid Coverage Fight
• Fla. Jury Says J&J Unit Is Owed $59.5M In Implant Patent Fight
• New Ill. Law Aims To Protect Out-Of-State Abortion Patients
• Law360 Names Practice Groups Of The Year
• Predictions For The 2023 Drug Pricing Landscape
• Bausch Hits Aurobindo With Gastro Drug Patent Suit
• 6 Questions For Boutique Firms Considering Mergers
• Time To Revisit A Little-Used Patent Tool
• Rubber Co. Fights Bid To Toss Hidden Labor Violation Suit
• 3M Wants Early Win Against Distributor In N95 Trademark Suit
• Supreme Court Will Scrutinize FCA's Scienter Standard
• 3 Legal Ethics Issues For Psychedelics Attorneys
• 10th Circ. To Mull Forced Arbitration Of ERISA Class Actions
• Biotech Co. Tricida Gets Bankruptcy Auction Fast-Tracked
• MRI Co., Receptionist Reach Deal To End Discrimination Suit
• Dow Chemical Wants Out Of Tech Firm's Trade Secrets Spat
• 'I've Had My Fill,' Ill. Judge Says In Express Scripts Suit
• Calif. Says Insulin Makers, PBMs Overcharge Diabetics
• Fed. Circ. Stuck On How To Appeal PTAB Policy In Fintiv Case
• Ex-Takeda Employee, Boyfriend Charged With $2.3M Fraud
• 3rd Circ. Presses US On Mylan's $50M Tax Bill For Court Costs
• Testing The Doctrine of Equivalents' Chemical Patent Context
• Paramedical Services Co. Settles TCPA Suit Over Robocalls
• Bain Capital Invests $400M In Biorefinery Co. EcoCeres
• Ex-NFL Player Drops 2 Defendants From Suit Over PPE Deal
• Biotech Tricida Hits Ch. 11 In Del. With $350M Debt, Sale Plans
• Acorda Says It's Owed $65M More In MS Drug Fight
• Duane Morris Boosts Silicon Valley Office With IP, Trial Pros
• Astellas Sues Chinese Rival To Block Generic Bladder Drug
• Walgreens Overcharges For Kids' Cough Medicine, Suit Claims
• Azurity Can't Duck Bionpharma's Sham Suit Claims
• Latest Illumina-Grail Appeal Challenges EU Separation Order
• 6 Takeaways From LabSolutions 'Unnecessary Testing' Verdict
• Ohio Pharma Board Must Reconsider Dispensary Application
• Mo. High Court Vacates $5M Geico Payout In HPV Suit
• Judge Pushes Resolution In Vanda, FDA Gastro Drug Fight
• Fennec Sues Cipla Over Generic Hearing Loss Treatment Bid
• The Issues Shaping Labor Market Antitrust Litigation In 2023
• Colo. Agency Calls For More Rules On Kratom Makers
• ITC Judge Rules That Apple Watch Infringes Masimo Patent
• Philips Stops Chinese Rivals From Using Stolen Trade Secrets
• 6th Circuit Won't Put Brakes On Ky. Securities Fraud Probe
• Tulane, Insurers Finalize Settlement Of COVID Coverage Suit
• FDA Drug Approvals Don't Include Impurities, DC Circ. Rules
• Pending Appeal, Balwani Asks To Stay Out Of Prison
• Bayer Sunscreen Settlement Nets Class Attys $766K
• Choctaw Nation Asks 9th Circ. To Reverse Arbitration Order
• Exploring The Amgen Genus Claims Headed To High Court
• Real Estate Rumors: Feil, Teva Pharmaceuticals, Somerset
• Chancery Class Seeks Rare AmerisourceBergen Ruling Redo
• Pa. Records Office Must Review Health Dept. Pot Recall Docs
• BioNTech To Buy Rest Of UK AI Startup Through $439M Deal
• Juul Founders Must Face NY AG's Underage Marketing Suit
• Midterm Cannabis Results Remind That Progress Is Not Linear
• Cipriani & Werner Sues Aurobindo Pharma For $3.8M MDL Tab
• Ex-Aegerion Rep In Talks With Feds To Avoid 2nd Fraud Trial
• 5 Tips For Adding Value To Legal Clients' Experience In 2023
• USPTO Strategic Plan Met With Praise, Calls For More Details
• 1st Circ. Backs GSK's Preemption Win Against Zofran MDL
• Resonetics To Buy Medical Materials Biz In Deal Worth $900M
• Bionpharma Can't Get Drug Patent Suit Tossed
• Novartis Gets OK On $126M Deal To End Drug Delay Claims
• Endo Ch. 11 Could Stiff Future Opioid Claimants, Judge Told
• Sterigenics To Pay $408M To End Over 870 Emissions Suits
• Arthrex Returns To High Court With Hirshfeld Challenge
• Justices Deny Juno Rehearing Bid After Amgen Cert. Grant
• 4 Key Issues Driving Drug Discount Abuse Must Be Addressed
• IQVIA Thwarts Research Co.'s Early Exit From Poaching Suit
• Lewis Brisbois, Weil Guide $335M Cancer Biotech SPAC Deal
• Justices Jilt Pfizer's Kickback Attack, But Dispute Isn't Done
• Fed. Circ. Patent Decisions In 2022: An Empirical Review
• Catching Up With Delaware's Chancery Court
• Lathrop GPM Adds Veteran Patent Prosecutor In Chicago
• Bayer's Ex-Top Lawyer Joins Software Giant SAP As GC
• Teva Says $4.3B Global Opioid Deal Can Move Ahead
• Bayer Whistleblower Attys Want $2.2M In Fees For FCA Suit
• Pharma Biz Sues PE Firm In Delaware, Alleging Raid On Staff
• 3 Firms Lead French Pharma Biz's $952M Biotech Co. Deal
• Greenberg Traurig Nabs Biotech IP Atty From Kasowitz
• Idaho, SC Top Courts Diverge On Abortion Access
• Linklaters' Partner Firm Adds Disputes Partner In Beijing
• FDA Clears New Alzheimer's Drug Amid Lingering Controversy
• Investor Sues To Halt $615M Boston Scientific Deal
• Amolyt Pharma Closes $138M Series C Round Of Financing
• Green Groups Fight Another Bid To Delay Fluoride Risks Case
• Fed. Circ. Says Thermo Fisher Can't Beat Interference Loss
• Cannabis Co. Can't Toss Investors' Stock Drop Suit
• 5 Major Drug And Device Developments Of 2022
• 11th Circ. Again Denies Shire's Bid To Dodge Label Case
• Health Hires: Kymera Therapeutics, Crown Laboratories
• UK Litigation Roundup: Here's What You Missed In London
• The Hottest FCA Cases & Trends To Watch In 2023
• Amgen Doesn't Want Chemistry Group's Help At High Court
• Lantus Buyers Line Up As Plaintiffs In Recast Class Action
• Altria Accuses Juul Of Hiding Vaping Settlement Details
• CBD Drug Co. Alleges Teva, Others Violated Patents
• 11th Circ. Axes Docs' Pill Convictions After High Court Ruling
• Investor Says Biotech Co. Hid Blood Treatment Funding Woes
• Bill Aims To Stomp Out Doping In NY Horse-Racing Industry
• Zimmer Buys Medical Tech Co. Embody For Up To $275M
• Horizon Therapeutics Investor Sues To Halt $28B Amgen Deal
• GenapSys Ch. 11 Plan Confirmed After $42M Asset Sale
• California Water District Joins 'Forever Chemicals' MDL
• Cahill Gordon Lands King & Spalding Patent Litigator
• 6th Circ. Orders Probe Of When Lilly Burglar Heard About Deal
• Goodwin Nabs Investment, Real Estate Partner In New York
• Invisalign Maker Says SmileDirect 'Built On A Lie' In New Suit
• Dinsmore Picks Up Ex-Middleton Reutlinger IP Pros
• Bills To Decriminalize Psychedelics Filed In 4 States
• Calbiotech Can't Avoid ERISA Suit Over Safe Harbor 401(k)
• 3rd Circ. Preview: NCAA Athlete Pay Fight Tops Jan. Calendar
• Key Takeaways From 2022 Trade Secret Developments
• Express Scripts Antitrust Suit Is 'Off The Rails,' Judge Says
• Abbott Wins $26M Against Retailer In Test Strips TM Row
• Priest, Hedge Fund Founder Can't Ax SEC's Win In Fraud Suit
• In Holmes' Sentencing, Judge Has Warning For All Companies
• Preparing For Congressional Oversight Of Chinese Trade
• FDA's 1st Cannabis Adviser May Mean CBD Regulation In 2023
• Enviro Group Sues FEMA For Info On Fossil Fuel Spending
• FDA Paves Way For Pharmacy Chains To Offer Abortion Pills
• Health & Pharma Legal Clashes Didn't Take A Holiday Break
• Tenn. And Wash. Join FTC's Generic Pesticide Blocking Suit
• Amgen Gets Broad Support In High Court Patent Fight
• Calif. Panel Sides With Restaurant After COVID-19 Settlement
• Fed. Circ. Won't Bar Generic Sleep Meds Amid Vanda Appeal
• Catching Up With Delaware's Chancery Court
• Potential Upheaval For FDA Regulation Of Stem Cell Clinics
• Fed. Circ. Backs Decision Clearing Pfizer On Heart Drug IP
• Mallinckrodt Tries To Stop Another Oxide Rival
• Ex-Lab Manager Says Takeda Unit Allowed Bias, Retaliation
• 6 Ways To Avoid Compounding Errors When Practicing Law
• 4 Firms Lead Med Tech, Clean Energy SPAC Deals
• Janssen Says Whistleblower Dragging Feet In Kickback Case
• Bankruptcy Cases And Trends To Watch In 2023
• Predictions In 3 Key Areas For IP Practitioners This Year
• Illinois Cases To Watch In 2023
• Top 10 Whistleblowing And Retaliation Events of 2022
• Where Key Patent Policy Issues Stand In 2023
• 2022: The Year In Psychedelic Law And Policy
• Health Care & Life Sciences Litigation To Watch In 2023
• State AGs May Double Down On Bipartisan Issues In 2023
• Patent Cases To Watch In 2023
• Top Product Liability Cases Of 2022
• 2 States Take The Lead On Regulating Psychedelics
• Health & Life Sciences Attys Share Policy Predictions For 2023
• California Cases To Watch In 2023
• Trials To Watch In 2023
• What Will Keep Legal Talent Professionals Up At Night In 2023
• The Cybersecurity Stories That Could Define 2023
• Product Liability Cases To Watch In 2023
• Gov't Contracts Cases To Watch In 2023
• Top 4 Gov't Contracting Policies To Watch In 2023